Ascletis Pharma Showcases Breakthrough Obesity Treatments at ADA 2026: Clinical Data on ASC30, ASC39, and ASC37
Ascletis Pharma Announces Major Advances in Obesity Portfoli...
Sign in to continue:
Ascletis Pharma Announces Major Advances in Obesity Portfoli...
Jacobio Pharmaceuticals Announces Intention to Conduct On-Ma...
Shenzhen Xunce Technology Announces Strategic Cooperation wi...
Everest Medicines Signs Exclusive Agreement to Develop and C...
New Focus Auto Tech Holdings Major Transaction Announcement ...
Hong Kong Gold Industry Group Announces Significant Asset Im...